Bioresorbable Coronary Stents Market: Market Size & Forecast 2026

Bioresorbable coronary stents are medical devices designed to treat coronary artery disease by providing temporary mechanical support to blocked vessels while releasing medication to prevent restenosis. Unlike permanent metallic stents, bioresorbable stents are manufactured from materials such as polylactic acid or magnesium alloys that dissolve within the vessel wall over a period of one to three years, restoring natural vessel function. The market has evolved from early commercial setbacks, including Abbott's 2017 discontinuation of its Absorb BVS product, toward next-generation devices with improved designs, thinner struts, and more favorable biocompatibility profiles.

• •The market is valued at approximately $0.36 billion in 2025 and expected to reach around $641 million by 2035
• •Bioresorbable stents dissolve naturally within the body, avoiding permanent implants and associated long-term risks
• •The market has matured following product discontinuations, with newer-generation platforms addressing earlier safety concerns

The increasing global burden of coronary artery disease, driven by rising rates of diabetes, hypertension, and sedentary lifestyles, is expanding the pool of patients requiring revascularization procedures. Growing adoption of minimally invasive interventional cardiology, coupled with improvements in bioresorbable stent technology including better strut thickness and drug-elution capabilities, is supporting market growth. Additionally, favorable clinical data demonstrating comparable short-term efficacy and improved long-term vascular remodeling compared to permanent stents are influencing physician and patient preferences.

• •Rising prevalence of cardiovascular disease and an aging global population are expanding the patient base requiring coronary interventions
• •Advancements in polymer and magnesium alloy technologies are improving device safety profiles and clinical outcomes
• •Increasing preference for bioresorbable solutions among interventional cardiologists seeking to avoid permanent vessel caging

The market is segmented by material type into polymer-based stents, which dominate current commercial offerings, and metal-based stents primarily utilizing magnesium alloys. Drug-eluting variants, including sirolimus- and novolimus-coated platforms, represent the leading product category. End-use segments include hospitals, cardiac specialty clinics, and ambulatory surgical centers, with hospitals accounting for the largest share of procedures. Geographically, North America and Europe lead the market due to established healthcare infrastructure and higher adoption of innovative interventional cardiology technologies, while Asia-Pacific is emerging as the fastest-growing region driven by expanding healthcare access and rising disease burden.

• •Polymer-based stents and metal-based magnesium alloy stents are the primary material categories
• •Drug-eluting platforms utilizing sirolimus and novolimus are the dominant product segment
• •North America and Europe lead in market share, with Asia-Pacific representing the fastest-growing regional market

What are the recent trends and outlook?

The market is moving toward third-generation bioresorbable scaffolds with ultra-thin struts, improved radial strength, and enhanced biocompatibility to address limitations of earlier devices. Integration of advanced imaging techniques, including optical coherence tomography, is enabling more precise implantation and better clinical monitoring. Regulatory bodies are actively evaluating and approving new-generation platforms, with an emphasis on robust clinical trial data demonstrating non-inferiority to existing standards. The long-term outlook suggests steady growth as healthcare systems increasingly prioritize technologies that reduce the lifetime burden of permanent implants and minimize late adverse events such as late stent thrombosis.

• •Next-generation bioresorbable stents with thinner struts and improved drug-elution profiles are entering the market
• •Optical coherence tomography-guided implantation is becoming a standard of care to optimize procedural outcomes
• •Continued clinical research and regulatory approvals are expected to drive broader adoption through 2035